Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing

Mei, Zhen; Wool, Geoffrey D.

doi:10.1016/j.hoc.2019.05.007

Cited by 11 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…29 Antiidiotype antibody and soluble recombinant CD38 are also reported to prevent binding of daratumumab with CD38-expressing reagent RBCs; 9 however, although the cost of reagent is minimal, this method is expensive and, like DTT, encumbered by an absence of resources not routinely available at many hospital blood banks. 9,16,30,31 In conclusion, the current study shows that both isatuximab and daratumumab interfere with IATs but at different magnitudes in vitro and in vivo, reflecting distinct binding to CD38. In in vitro binding studies, CD38 expressed by RBCs can be directly recognized by daratumumab, whereas isatuximab requires a co-factor, such as a mouse anti-CD38 antibody (HB-7 or AT13/5) or a CD38 inhibitor, suggesting that the isatuximab epitope on RBCs is masked.…”

Section: Isatuximab Interference In the Clinical Settingmentioning

confidence: 58%

“…Other methods of avoiding anti‐CD38 interference include the use of trypsin, a proteolytic enzyme that decreases daratumumab binding to CD38‐expressing cells, but it is not as extensively used as DTT 29 . Anti‐idiotype antibody and soluble recombinant CD38 are also reported to prevent binding of daratumumab with CD38‐expressing reagent RBCs; 9 however, although the cost of reagent is minimal, this method is expensive and, like DTT, encumbered by an absence of resources not routinely available at many hospital blood banks 9,16,30,31 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping

et al. 2022

View full text Add to dashboard Cite

Background: There are two FDA-approved anti-CD38 monoclonal antibodies for treatment of multiple myeloma: isatuximab and daratumumab. Owing to expression of CD38 on reagent red blood cells (RBCs), these antibodies interfere with indirect antiglobulin tests (IATs). We sought to understand differences in such interference by performing binding experiments. Study Design and Methods: In vitro experiments to compare the binding to RBCs of isatuximab and daratumumab alone or in the presence of a mouse anti-human CD38 antibody (HB-7 or AT13/5) or a nicotinamide adenine dinucleotide-analog CD38 inhibitor were performed and quantified by flow cytometry, imaging, mass spectrometry, surface plasmon resonance, and LigandTracer technologies. Serologic testing was performed on plasma samples spiked with isatuximab or daratumumab. Results: CD38 expressed on RBCs can be directly bound by daratumumab, whereas isatuximab requires a co-factor, such as HB-7, AT13/5, or a CD38

show abstract

Section: Isatuximab Interference In the Clinical Settingmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Among them, 98 cases of MM, 22 cases of chronic lymphocytic leukemia and 16 cases of relapsed acute myeloid leukemia as shown in Table 1. CD38 monoclonal antibody is daratumab [14][15][16][17][18] . In addition to daratumab (Janssen Biotech), other anti-CD38 drugs currently in Phase 1 or 2 clinical trials include MOR202 (MorPhoSys), isatuximab (Sanofi-Aventis) and TAK-079 (Takeda), which were adopted for systemic lupus erythematosus or other autoimmune diseases treatment.…”

Section: Resultsmentioning

confidence: 99%

Interference Analysis of Monoclonal Antibody Cluster of Differentiation 38 on ABO Blood Group Identification and Cross-Matching

Wang¹,

Qiu²,

Shao³

et al. 2022

IJPS

View full text Add to dashboard Cite

We attempt to analyze and adopt the interference of monoclonal antibody cluster of differentiation 38 on ABO blood group identification and cross-matching. Search PubMed, Medline, Web of Science, China National Knowledge Infrastructure, Wanfang and other domestic and foreign databases, screening of patients requiring blood transfusion after receiving anti-cluster of differentiation 38 monoclonal antibody, retrospective analysis of anti-human globulin cassette method for antibody screening and cross-matching of serum from patients treated with cluster of differentiation 38 monoclonal antibody. According to the search results, a total of 185 patients who received cluster of differentiation 38 as monotherapy or combination therapy and required blood transfusion were retrieved. Among them, 98 cases of multiple myeloma, 22 cases of chronic lymphocytic leukemia and 16 cases of relapsed acute myeloid leukemia, total was 136 cases. But among the 124 patients who received daratumab treatment, a total of 49 patients (39.5 %) received 236 blood transfusions during treatment. Among these, 47 patients (37.9 %) received 147 red blood cell infusions, 17 patients (13.7 %) received 89 platelet transfusions. Among the systemic lupus erythematosus patients, there was only one case of transfusion-related reactions after platelet (rather than red blood cell) transfusion and no other adverse reactions. In the investigation of multiple bone marrow-related diseases, we found that 5 cases developed indirect antiglobulin test and were weakly positive, all patients did not see any discrepancies in ABO blood type identification. Antibody identified panagglutination occurred in only 1 patient with multiple myeloma. Among the multiple myeloma patients, cluster of differentiation 38 possessed a low expression on the surface of erythrocytes and its level on erythrocytes does not differ between individuals. After anti-cluster of differentiation 38 injections, macrophages increased, i.e. the antigen of cluster of differentiation 38 molecules in the patient's own erythrocyte falls off. Cluster of differentiation 38 monoclonal antibody substantially made no interference with ABO, rhesus or extended antigen matching. In antibody screening and cross-matching, cluster of differentiation 38 monoclonal antibody caused interference only at indirect antiglobulin test, showing antibody agglutination intensity 1 + or weaker reactivity. Hematological diseases such as multiple myeloid in antibody screening and cross-matching, anticluster of differentiation 38 antibody only caused interference in indirect antiglobulin test, showing weaker reactivity; cluster of differentiation 38 monoclonal antibody substantially made no interference with ABO, rhesus or extended antigen matching.

show abstract

“…CD47 is a ubiquitously expressed surface glycoprotein and anti-phagocytic marker which regulates cell survival and is overexpressed in a broad range of tumors. 2 Administration of CD47 antibodies can be associated with the decline in hemoglobin levels and broad interference in pre-transfusion testing, 3 similar to daratumumab. However, anti-CD47 agents differ from daratumumab in that pan-reactivity cannot be selectively removed through commonly available in vitro manipulation, such as the use of DTT-treated reagent RBCs.…”

mentioning

confidence: 99%

Alloimmunization rates in transfused patients receiving anti‐CD47 antibody therapy

et al. 2022

Self Cite

View full text Add to dashboard Cite

Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing

Cited by 11 publications

References 50 publications

Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping

Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping

Interference Analysis of Monoclonal Antibody Cluster of Differentiation 38 on ABO Blood Group Identification and Cross-Matching

Alloimmunization rates in transfused patients receiving anti‐CD47 antibody therapy

Contact Info

Product

Resources

About